TY - JOUR
T1 - Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm
T2 - a multicenter study from the Okayama Hematological Study Group
AU - Kitamura, Wataru
AU - Fujii, Nobuharu
AU - Nawa, Yuichiro
AU - Fujishita, Keigo
AU - Sugiura, Hiroyuki
AU - Yoshioka, Takanori
AU - Fujiwara, Yuki
AU - Usui, Yoshiaki
AU - Fujii, Keiko
AU - Fujiwara, Hideaki
AU - Asada, Noboru
AU - Nishimori, Hisakazu
AU - Matsuoka, Ken ichi
AU - Maeda, Yoshinobu
N1 - Funding Information:
We thank all the patients who participated in this study. We are also grateful to Dr. Toshi Imai, Dr. Toru Kiguchi, and Dr. Yasushi Hiramatsu for their help in our research. The manuscript for English language was edited and proofread by Enago (https://www.enago.jp ).
Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2022/4
Y1 - 2022/4
N2 - Background: Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group). Methods: We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo. Results: The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (p < 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (p = 0.03). Conclusions: The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.
AB - Background: Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group). Methods: We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo. Results: The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (p < 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (p = 0.03). Conclusions: The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Minimal residual disease
KW - Myeloid neoplasm
KW - Posttransplant cyclophosphamide
KW - Wilms’ tumor 1
UR - http://www.scopus.com/inward/record.url?scp=85124278269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124278269&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03290-3
DO - 10.1007/s12185-022-03290-3
M3 - Article
C2 - 35119651
AN - SCOPUS:85124278269
VL - 115
SP - 515
EP - 524
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 4
ER -
